

● INVITED REVIEW

Connexins in neurons and glia: targets for intervention in disease and injury

Keith B. Moore¹, John O'Brien^{1,2,*}

1 Richard S. Ruiz, M.D. Department of Ophthalmology & Visual Science, The University of Texas Health Science Center at Houston, TX, USA

2 The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA

***Correspondence to:**

John O'Brien, Ph.D.,
John.O'Brien@uth.tmc.edu.

doi:10.4103/1673-5374.160092

<http://www.nrronline.org/>

Accepted: 2015-05-14

Abstract

Both neurons and glia throughout the central nervous system are organized into networks by gap junctions. Among glia, gap junctions facilitate metabolic homeostasis and intercellular communication. Among neurons, gap junctions form electrical synapses that function primarily for communication. However, in neurodegenerative states due to disease or injury gap junctions may be detrimental to survival. Electrical synapses may facilitate hyperactivity and bystander killing among neurons, while gap junction hemichannels in glia may facilitate inflammatory signaling and scar formation. Advances in understanding mechanisms of plasticity of electrical synapses and development of molecular therapeutics to target glial gap junctions and hemichannels offer new hope to pharmacologically limit neuronal degeneration and enhance recovery.

Key Words: ischemia; retinal degeneration; amacrine cells; astrocytes, dopamine receptors; adenosine receptors, NMDA receptors; connexin mimetic peptides

Funding: This work is supported by NIH grant R01EY012857 (JO), the Frederic B. Asche endowment and Research to Prevent Blindness. KBM is supported by T32EY007024.

Moore KB, O'Brien J (2015) Connexins in neurons and glia: targets for intervention in disease and injury. *Neural Regen Res* 10(7):1013-1017.

Abundant Gap Junctions in the Central Nervous System (CNS)

The organization of tissues into intricate systems is an essential element of life for multicellular organisms. One of the critical mediators of this organization is the gap junction, which permits direct intercellular communication between neighboring cells. Within the vertebrate central nervous system astrocytes, oligodendrocytes and ependymal cells are independently coupled by gap junctions, with some interconnections. This glial syncytium is critical for support of healthy nervous tissue.

Neurons are also coupled by gap junctions, which form electrical synapses. Electrical synapses permit direct electrical communication between two cells as well as allow passage of some cytoplasmic small molecules (Bennett and Zukin, 2004). Electrical synapses serve unique purposes separate from those of chemical synapses. Electrical synapses between like neurons expand receptive field sizes, dampen non-correlated noise and coordinate activity. Between dissimilar cell types, they establish specialized feed forward synaptic circuits that play prominent known roles in signaling in the retina, hindbrain and spinal cord (Bloomfield and Volgyi, 2009; Pereda et al., 2013). The unexpected abundance of these heterologous electrical synapses in the CNS (Rash et al., 2015) suggests that they play a number of important roles that are not yet known.

Knockout of Connexin36 (*Cx36* or *gid2*), the most prevalent gap junction gene expressed in neurons, has revealed that electrical coupling is important for learning and memory (Frisch et al., 2005; Van Der Giessen et al., 2008), synapse development (Personius et al., 2007), and scotopic visual signaling (Guldenagel et al., 2001; Abd-El-Barr et al., 2009). Recognition that electrical synapses play a role in a variety of neurological disorders has also been growing in the last decade. Reduced function of electrical synapses has been proposed to underlie autism (Welsh et al., 2005), while their hyper-function may lead to seizure (Traub et al., 2004; Cunningham et al., 2012). These and many other findings highlight the important roles played by electrical synapses and suggest that pharmacological modulation of their activity presents a useful strategy for therapy for some neurological disorders.

The Role of Gap Junctions in Neural Disease and Injury

Cx36 gap junctions are prevalent in neurons throughout the CNS, with increased expression during early development and tapering off in adults (Belousov and Fontes, 2013). Transiently increased levels of gap junctions and electrical coupling are also observed immediately following ischemic injury to the CNS (Oguro et al., 2001; Nakase et al., 2004; Wang et al., 2012), in multiple models of epilepsy (Gajda et al., 2003), and traumatic brain injury (Frantseva et al., 2002;




Figure 1 Schematic representation of some of the signaling pathways that control electrical coupling in neurons and contribute to inflammatory signaling by astrocytes.

Protein kinase signaling pathways potentiated by N-methyl-D-aspartate (NMDA) receptors and A2a adenosine receptors are potentially important pathways that increase neuronal coupling and may enhance bystander killing. Note that each signaling mechanism shown is not present on all neurons. See O'Brien, 2014a, b for more detail of electrical synaptic signaling pathways. Connexin hemichannels in activated astrocytes can release substances that cause excitotoxicity and promote inflammation. Adenosine triphosphate (ATP) release also propagates signaling through the network of astrocytes. See Orellana and Stehberg, 2014 for more detailed review of astrocytic hemichannel signaling.

Ohsumi et al., 2006). In models of retinal degeneration, neural network remodeling is accompanied by excessive activity among spiking neurons (Menzler and Zeck, 2011; Trenholm et al., 2012). This activity is strongly dependent on gap junction coupling (Toychiev et al., 2013; Choi et al., 2014). The excessive coupling in damaged neural networks has negative consequences for neuron survival as the extent of death is greatly reduced in Cx36 knockout animals or when gap junction inhibitors are applied (Talhok et al., 2008; Paschon et al., 2012; Belousov and Fontes, 2013).

Propagation of neural injury to uninjured neighbors is a form of bystander killing. Bystander killing is a well-documented process in which cells that are close neighbors of damaged cells or those undergoing apoptosis are also killed. This effect has been widely exploited in the treatment of tumors with suicide gene therapy or ionizing radiation, and the efficacy of bystander killing has been linked to the presence of gap junctions in the tumor cells (Fick et al., 1995; Mesnil et al., 1996). A bystander killing effect is also evident in experimental models of retinal injury (Cusato et al., 2003; Akopian et al., 2014). Gap junctions are an attractive target for therapeutic intervention, since prevention of bystander killing and aberrant activity can significantly reduce the extent of damage following injury or disease.

Connexins in glia play critical and somewhat complicated roles in neural injury and disease. Connexin 43 (Cx43 or Gja1), the primary connexin forming gap junctions among

astrocytes in most of the CNS, also efficiently forms gap junction hemichannels under some conditions (Contreras et al., 2002) (Figure 1). Astrocytic gap junctions and hemichannels seem to play very different roles in neural injury. Gap junctions among astrocytes appear to enhance neuron viability during the initial phase of an ischemic injury. In a middle cerebral artery ischemia model, knock-out of Cx43 in astrocytes resulted in increased stroke volume, apoptosis and inflammatory signaling compared to controls (Nakase et al., 2004). However, substantial evidence suggests that gap junction hemichannels also contribute to inflammatory signaling and the spread of ischemic brain injury (Davidson et al., 2013b; Orellana and Stehberg, 2014). An increase in gap junctions and gap junction hemichannels is also a characteristic component of reactive gliosis in Alzheimer's disease (Koulakoff et al., 2012) and potentially other progressive neurodegenerative diseases, contributing to inflammatory signaling. Thus strategies to mitigate neuronal degeneration in injury and neurodegenerative diseases could be refined through knowledge of the different forms of signaling regulating gap junctions and hemichannels in neurons and glia.

Physiological Regulation of Gap Junctions in the CNS

A potentially useful strategy to minimize neuronal degeneration during injury or degenerative diseases is to specifically

target neuronal gap junctions and glial gap junction hemichannels during critical periods. Gap junction inhibitors are fairly non-specific and systemic administration is complicated due to the critical role of gap junctions in cardiac function. However, interventions can be designed to reduce neuronal electrical coupling by targeting signaling pathways that control physiological plasticity, potentially reducing the damage caused by ischemic events, seizures, or traumatic brain injuries.

Research in retinal neurons has revealed that many electrical synapses display a high degree of plasticity (O'Brien, 2014a). This plasticity is observed in response to light adaptation and is regulated by a variety of signaling pathways. Coupling among retinal AII amacrine cells is regulated by light in a biphasic pattern, with very low coupling under conditions of prolonged complete dark adaptation or bright light adaptation, and maximal coupling at intermediate light levels (Bloomfield and Volgyi, 2004). Kothmann et al. (2009) found that these changes in coupling were directly correlated to phosphorylation of Cx36 at certain regulatory sites, with the phosphorylation state of Cx36 linearly correlated with coupling over more than an order of magnitude dynamic range in coupling. The light-induced increase in coupling resulted from Calcium-Calmodulin-dependent kinase II (CamKII) phosphorylation of Cx36 driven by Ca^{2+} influx through non-synaptic N-methyl-D-aspartate (NMDA) receptors (**Figure 1**) activated by glutamatergic bipolar cells (Kothmann et al., 2012). In brighter light conditions, stimulation of dopamine release in the retina activates a complex signaling pathway that dephosphorylates Cx36. Dopamine activates D1 dopamine receptors on AII amacrine cells that in turn activate protein kinase A (PKA) (Hampson et al., 1992; Mills and Massey, 1995). PKA activity in turn activates protein phosphatase 2A, resulting in net dephosphorylation of Cx36 (Kothmann et al., 2009; O'Brien, 2014b). While the signaling is best described in retinal neurons, there are many examples of similar electrical synaptic plasticity elsewhere in the brain, including activity- and CamKII-dependent increases in coupling (Pereda et al., 1998; Turecek et al., 2014) and dopamine-dependent decreases in coupling (Rorig et al., 1995).

In contrast to retinal AII amacrine cells, retinal photoreceptors use a somewhat different mechanism to control coupling (Li and O'Brien, 2012; O'Brien, 2014a). Photoreceptor coupling changes profoundly under control of a circadian rhythm (Ribelayga et al., 2008), with extensive coupling at night and low coupling in the day and in bright light adapted states. This coupling is also controlled by phosphorylation of Cx36 at the same sites, but depends directly and positively on PKA activity, in contrast to the negative regulation by PKA in AII amacrine cells (Li et al., 2009, 2013). Cx36 phosphorylation and PKA activity are controlled in photoreceptors by bidirectional signaling from G-protein coupled dopamine and adenosine receptors to adenylyl cyclase (AC) (Li et al., 2013, 2014) (**Figure 1**). High levels of dopamine in the daytime activate D4 dopamine receptors to inhibit AC

while high levels of adenosine at night activate A2a adenosine receptors to activate the cyclase (Li et al., 2013). While retinal adenosine levels are lower in the daytime and in bright light-adapted conditions, the daytime level of adenosine does activate A1 adenosine receptors that inhibit AC, reinforcing the dopamine effect (Li et al., 2014). Thus photoreceptor coupling is controlled very precisely by a balance of extracellular signaling cues reported by G-protein coupled receptors.

A variety of other signaling mechanisms have been described that regulate electrical synapses in different parts of the brain. These include plasticity controlled by nitric oxide (Mills and Massey, 1995; Patel et al., 2006), histamine receptors (Hatton and Yang, 2001; Yang and Hatton, 2002), cannabinoid receptors (Cachope et al., 2007), and metabotropic glutamate receptors (Haas et al., 2011). The latter are also critical for the post-injury increase in expression of Cx36 in CNS tissues (Park et al., 2011). The host of different mechanisms that regulate coupling in different neural circuits underscores the fact that the mechanisms of plasticity are specific to each type of neuron. However, there is ample evidence that certain regulatory behaviors, which we might refer to as 'regulatory modules,' recur in many types of neurons in many areas of the CNS (O'Brien, 2014b). These modules represent attractive targets for pharmacological intervention and require the development of an adequate understanding of their prevalence and distribution in the CNS to develop targeted therapies for diseases and injuries.

Therapeutic Targeting of Gap Junctions in CNS Disorders

Knowledge of signaling pathways that control plasticity of electrical synapses is expanding rapidly, and it is now possible to consider therapeutic strategies that target these pathways in treatments for neurological diseases and injuries. NMDA receptor antagonists, widely studied for their neuroprotective potential to reduce excitotoxicity, are also important targets to reduce electrical coupling and bystander killing. Linkage of non-synaptic NMDA receptor activation to potentiation of electrical synapses is likely to be very widespread in the CNS (O'Brien, 2014b). Inhibition of adenosine A2a receptors, useful targets to suppress inflammatory signaling, should also suppress coupling in some neuronal networks.

The use of connexin mimetic peptides has shown promise in therapeutic treatment for a number of disease and injury models. The vast majority of these peptides focus on Cx43, which is found in most mammalian tissues. A Cx43 mimetic α CT1, mimicking the carboxy terminus of Cx43, was shown to significantly increase corneal wound healing in a traumatic wound injury model *in vivo* for both WT and STZ diabetic rat models when applied in a microencapsulated form (Moore et al., 2013, 2014). Retinal reperfusion and ischemia models testing a Cx43 mimetic targeting an

extracellular loop transiently blocked Cx43 activity, leading to a reduction in vascular leaking and ganglion cell death post injury (Danesh-Meyer et al., 2012; Kerr et al., 2012). The therapeutic actions of the peptide are thought to center on blockage of Cx43 hemichannel activity, as revealed by a reduction in inflammatory signaling. This hypothesis was examined further in an optic neuropathy model by Chen et al. (2013), using mimetic peptides stabilized with lipoamino acid groups to create long term blockage of hemichannels, and thus curtailing retinal cell death. Using a similar blockade of Cx43 with mimetics in a fetal sheep global cerebral ischemia model led to reduction of seizures, increased cell survival, and improvements in sleep state cycle (Davidson et al., 2012, 2013a). Cx43 mimetics also reduced long term developmental defects, increased cell recovery, and reduced neuronal damage *in vivo* using models of epilepsy and preterm asphyxia associated with cerebral palsy (Samoilova et al., 2008; Davidson et al., 2014; Mylvaganam et al., 2014). The therapeutic applications of connexin mimetic peptides have so far been limited to connexins that would be present in glia and vascular tissues in the CNS. It is reasonable to expect that strategies combining mimetic peptides to target glial and endothelial gap junction hemichannels with drugs targeting electrical synaptic signaling pathways may further improve survival of neurons in neurodegenerative diseases and injuries.

References

- Abd-El-Barr MM, Pennesi ME, Saszik SM, Barrow AJ, Lem J, Bramblett DE, Paul DL, Frishman LJ, Wu SM (2009) Genetic dissection of rod and cone pathways in the dark-adapted mouse retina. *J Neurophysiol* 102:1945-1955.
- Akopian A, Atlasz T, Pan F, Wong S, Zhang Y, Volgyi B, Paul DL, Bloomfield SA (2014) Gap junction-mediated death of retinal neurons is connexin and insult specific: a potential target for neuroprotection. *J Neurosci* 34:10582-10591.
- Belousov AB, Fontes JD (2013) Neuronal gap junctions: making and breaking connections during development and injury. *Trends Neurosci* 36:227-236.
- Bennett MV, Zukin RS (2004) Electrical coupling and neuronal synchronization in the Mammalian brain. *Neuron* 41:495-511.
- Bloomfield SA, Volgyi B (2004) Function and plasticity of homologous coupling between AII amacrine cells. *Vision Res* 44:3297-3306.
- Bloomfield SA, Volgyi B (2009) The diverse functional roles and regulation of neuronal gap junctions in the retina. *Nat Rev Neurosci* 10:495-506.
- Cachope R, Mackie K, Triller A, O'Brien J, Pereda AE (2007) Potentiation of electrical and chemical synaptic transmission mediated by endocannabinoids. *Neuron* 56:1034-1047.
- Chen YS, Toth I, Danesh-Meyer HV, Green CR, Rupenthal ID (2013) Cytotoxicity and vitreous stability of chemically modified connexin43 mimetic peptides for the treatment of optic neuropathy. *J Pharm Sci* 102:2322-2331.
- Choi H, Zhang L, Cembrowski MS, Sabottke CF, Markowitz AL, Butts DA, Kath WL, Singer JH, Riecke H (2014) Intrinsic bursting of AII amacrine cells underlies oscillations in the rd1 mouse retina. *J Neurophysiol* 112:1491-1504.
- Contreras JE, Sanchez HA, Eugenin EA, Speidel D, Theis M, Willecke K, Bukauskas FF, Bennett MV, Saez JC (2002) Metabolic inhibition induces opening of unapposed connexin 43 gap junction hemichannels and reduces gap junctional communication in cortical astrocytes in culture. *Proc Natl Acad Sci U S A* 99:495-500.
- Cunningham MO, Roopun A, Schofield IS, Whittaker RG, Duncan R, Russell A, Jenkins A, Nicholson C, Whittington MA, Traub RD (2012) Glissandi: transient fast electrocorticographic oscillations of steadily increasing frequency, explained by temporally increasing gap junction conductance. *Epilepsia* 53:1205-1214.
- Cusato K, Bosco A, Rozental R, Guimaraes CA, Reese BE, Linden R, Spray DC (2003) Gap junctions mediate bystander cell death in developing retina. *J Neurosci* 23:6413-6422.
- Danesh-Meyer HV, Kerr NM, Zhang J, Eady EK, O'Carroll SJ, Nicholson LF, Johnson CS, Green CR (2012) Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia. *Brain* 135:506-520.
- Davidson JO, Green CR, Nicholson LF, Bennet L, Gunn AJ (2013a) Connexin hemichannel blockade is neuroprotective after, but not during, global cerebral ischemia in near-term fetal sheep. *Exp Neurol* 248:301-308.
- Davidson JO, Drury PP, Green CR, Nicholson LF, Bennet L, Gunn AJ (2014) Connexin hemichannel blockade is neuroprotective after asphyxia in preterm fetal sheep. *PLoS One* 9:e96558.
- Davidson JO, Green CR, Nicholson LF, O'Carroll SJ, Fraser M, Bennet L, Gunn AJ (2012) Connexin hemichannel blockade improves outcomes in a model of fetal ischemia. *Ann Neurol* 71:121-132.
- Davidson JO, Green CR, Bennet L, Nicholson LF, Danesh-Meyer H, O'Carroll SJ, Gunn AJ (2013b) A key role for connexin hemichannels in spreading ischemic brain injury. *Curr Drug Targets* 14:36-46.
- Fick J, Barker FG, 2nd, Dazin P, Westphale EM, Beyer EC, Israel MA (1995) The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. *Proc Natl Acad Sci U S A* 92:11071-11075.
- Frantseva MV, Kokarovtseva L, Naus CG, Carlen PL, MacFabe D, Perez Velazquez JL (2002) Specific gap junctions enhance the neuronal vulnerability to brain traumatic injury. *J Neurosci* 22:644-653.
- Frisch C, De Souza-Silva MA, Sohl G, Guldenagel M, Willecke K, Huston JP, Dere E (2005) Stimulus complexity dependent memory impairment and changes in motor performance after deletion of the neuronal gap junction protein connexin36 in mice. *Behav Brain Res* 157:177-185.
- Gajda Z, Gyengesi E, Hermes E, Ali KS, Sente M (2003) Involvement of gap junctions in the manifestation and control of the duration of seizures in rats in vivo. *Epilepsia* 44:1596-1600.
- Guldenagel M, Ammermuller J, Feigenspan A, Teubner B, Degen J, Sohl G, Willecke K, Weiler R (2001) Visual transmission deficits in mice with targeted disruption of the gap junction gene connexin36. *J Neurosci* 21:6036-6044.
- Haas JS, Zavala B, Landisman CE (2011) Activity-dependent long-term depression of electrical synapses. *Science* 334:389-393.
- Hampson EC, Vaney DI, Weiler R (1992) Dopaminergic modulation of gap junction permeability between amacrine cells in mammalian retina. *J Neurosci* 12:4911-4922.
- Hatton GI, Yang QZ (2001) Ionotropic histamine receptors and H2 receptors modulate supraoptic oxytocin neuronal excitability and dye coupling. *J Neurosci* 21:2974-2982.
- Kerr NM, Johnson CS, Zhang J, Eady EK, Green CR, Danesh-Meyer HV (2012) High pressure-induced retinal ischaemia reperfusion causes upregulation of gap junction protein connexin43 prior to retinal ganglion cell loss. *Exp Neurol* 234:144-152.
- Kothmann WW, Massey SC, O'Brien J (2009) Dopamine-stimulated dephosphorylation of connexin 36 mediates AII amacrine cell uncoupling. *J Neurosci* 29:14903-14911.
- Kothmann WW, Trexler EB, Whitaker CM, Li W, Massey SC, O'Brien J (2012) Nonsynaptic NMDA Receptors Mediate Activity-Dependent Plasticity of Gap Junctional Coupling in the AII Amacrine Cell Network. *J Neurosci* 32:6747-6759.
- Koulakoff A, Mei X, Orellana JA, Saez JC, Giaume C (2012) Glial connexin expression and function in the context of Alzheimer's disease. *Biochim Biophys Acta* 1818:2048-2057.
- Li H, O'Brien J (2012) Regulation of gap junctional coupling in photoreceptors. In: *Photoreceptors: Physiology, Types and Abnormalities* (Akutagawa E, Ozaki K, eds), pp 97-112. Hauppauge, NY: Nova Science.

- Li H, Chuang AZ, O'Brien J (2009) Photoreceptor coupling is controlled by connexin 35 phosphorylation in zebrafish retina. *J Neurosci* 29:15178-15186.
- Li H, Chuang AZ, O'Brien J (2014) Regulation of photoreceptor gap junction phosphorylation by adenosine in zebrafish retina. *Vis Neurosci* 31:237-243.
- Li H, Zhang Z, Blackburn MR, Wang SW, Ribelayga CP, O'Brien J (2013) Adenosine and Dopamine Receptors Coregulate Photoreceptor Coupling via Gap Junction Phosphorylation in Mouse Retina. *J Neurosci* 33:3135-3150.
- Menzler J, Zeck G (2011) Network oscillations in rod-degenerated mouse retinas. *J Neurosci* 31:2280-2291.
- Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. *Proc Natl Acad Sci U S A* 93:1831-1835.
- Mills SL, Massey SC (1995) Differential properties of two gap junctional pathways made by AII amacrine cells. *Nature* 377:734-737.
- Moore K, Ghatnekar G, Gourdie RG, Potts JD (2014) Impact of the controlled release of a connexin 43 peptide on corneal wound closure in an STZ model of type I diabetes. *PLoS One* 9:e86570.
- Moore K, Bryant ZJ, Ghatnekar G, Singh UP, Gourdie RG, Potts JD (2013) A synthetic connexin 43 mimetic peptide augments corneal wound healing. *Exp Eye Res* 115:178-188.
- Mylvaganam S, Ramani M, Krawczyk M, Carlen PL (2014) Roles of gap junctions, connexins, and pannexins in epilepsy. *Front Physiol* 5:172.
- Nakase T, Sohl G, Theis M, Willecke K, Naus CC (2004) Increased apoptosis and inflammation after focal brain ischemia in mice lacking connexin43 in astrocytes. *Am J Pathol* 164:2067-2075.
- O'Brien J (2014a) Regulation of Electrical Synaptic Plasticity in the Retina by G-Protein-Coupled Receptors. In: *G Protein Signaling Mechanisms in the Retina* (Martemyanov KA, Sampath AP, eds), pp 143-169. New York: Springer.
- O'Brien J (2014b) The ever-changing electrical synapse. *Curr Opin Neurobiol* 29C:64-72.
- Oguro K, Jover T, Tanaka H, Lin Y, Kojima T, Oguro N, Grooms SY, Bennett MV, Zukin RS (2001) Global ischemia-induced increases in the gap junctional proteins connexin 32 (Cx32) and Cx36 in hippocampus and enhanced vulnerability of Cx32 knock-out mice. *J Neurosci* 21:7534-7542.
- Ohsumi A, Nawashiro H, Otani N, Ooigawa H, Toyooka T, Yano A, Nomura N, Shima K (2006) Alteration of gap junction proteins (connexins) following lateral fluid percussion injury in rats. *Acta Neurochir Suppl* 96:148-150.
- Orellana JA, Stehberg J (2014) Hemichannels: new roles in astroglial function. *Front Physiol* 5:193.
- Park WM, Wang Y, Park S, Denisova JV, Fontes JD, Belousov AB (2011) Interplay of chemical neurotransmitters regulates developmental increase in electrical synapses. *J Neurosci* 31:5909-5920.
- Paschon V, Higa GS, Resende RR, Britto LR, Kihara AH (2012) Blocking of connexin-mediated communication promotes neuroprotection during acute degeneration induced by mechanical trauma. *PLoS One* 7:e45449.
- Patel LS, Mitchell CK, Dubinsky WP, O'Brien J (2006) Regulation of gap junction coupling through the neuronal connexin Cx35 by nitric oxide and cGMP. *Cell Commun Adhes* 13:41-54.
- Pereda AE, Curti S, Hoge G, Cachope R, Flores CE, Rash JE (2013) Gap junction-mediated electrical transmission: Regulatory mechanisms and plasticity. *Biochim Biophys Acta* 1828:134-146.
- Pereda AE, Bell TD, Chang BH, Czernik AJ, Nairn AC, Soderling TR, Faber DS (1998) Ca^{2+} /calmodulin-dependent kinase II mediates simultaneous enhancement of gap-junctional conductance and glutamatergic transmission. *Proc Natl Acad Sci U S A* 95:13272-13277.
- Personius KE, Chang Q, Mentis GZ, O'Donovan MJ, Balice-Gordon RJ (2007) Reduced gap junctional coupling leads to uncorrelated motor neuron firing and precocious neuromuscular synapse elimination. *Proc Natl Acad Sci U S A* 104:11808-11813.
- Rash JE, Kamasawa N, Vanderpool KG, Yasumura T, O'Brien J, Nannapaneni S, Pereda AE, Nagy JI (2015) Heterotypic gap junctions at glutamatergic mixed synapses are abundant in goldfish brain. *Neuroscience* 285:166-193.
- Ribelayga C, Cao Y, Mangel SC (2008) The circadian clock in the retina controls rod-cone coupling. *Neuron* 59:790-801.
- Rorig B, Klaus G, Sutor B (1995) Dye coupling between pyramidal neurons in developing rat prefrontal and frontal cortex is reduced by protein kinase A activation and dopamine. *J Neurosci* 15:7386-7400.
- Samoilova M, Wentlandt K, Adamchik Y, Velumian AA, Carlen PL (2008) Connexin 43 mimetic peptides inhibit spontaneous epileptiform activity in organotypic hippocampal slice cultures. *Exp Neurol* 210:762-775.
- Talhok RS, Zeinieh MP, Mikati MA, El-Sabban ME (2008) Gap junctional intercellular communication in hypoxia-ischemia-induced neuronal injury. *Prog Neurobiol* 84:57-76.
- Toychiev AH, Ivanova E, Yee CW, Sagdullaev BT (2013) Block of gap junctions eliminates aberrant activity and restores light responses during retinal degeneration. *J Neurosci* 33:13972-13977.
- Traub RD, Michelson-Law H, Bibbig AE, Buhl EH, Whittington MA (2004) Gap junctions, fast oscillations and the initiation of seizures. *Adv Exp Med Biol* 548:110-122.
- Trenholm S, Borowska J, Zhang J, Hoggarth A, Johnson K, Barnes S, Lewis TJ, Awatramani GB (2012) Intrinsic oscillatory activity arising within the electrically coupled AII amacrine-ON cone bipolar cell network is driven by voltage-gated Na^{+} channels. *J Physiol* 590:2501-2517.
- Turecek J, Yuen GS, Han VZ, Zeng XH, Bayer KU, Welsh JP (2014) NMDA receptor activation strengthens weak electrical coupling in mammalian brain. *Neuron* 81:1375-1388.
- Van Der Giessen RS, Koekkoek SK, van Dorp S, De Gruijl JR, Cupido A, Khosrovani S, Dortland B, Wellershaus K, Degen J, Deuchars J, Fuchs EC, Monyer H, Willecke K, De Jeu MT, De Zeeuw CI (2008) Role of olivary electrical coupling in cerebellar motor learning. *Neuron* 58:599-612.
- Wang Y, Song JH, Denisova JV, Park WM, Fontes JD, Belousov AB (2012) Neuronal gap junction coupling is regulated by glutamate and plays critical role in cell death during neuronal injury. *J Neurosci* 32:713-725.
- Welsh JP, Ahn ES, Placantonakis DG (2005) Is autism due to brain desynchronization? *Int J Dev Neurosci* 23:253-263.
- Yang QZ, Hatton GI (2002) Histamine H1-receptor modulation of inter-neuronal coupling among vasopressinergic neurons depends on nitric oxide synthase activation. *Brain Res* 955:115-122.